ArticleClinical cancer research : an official journal of the American Association for Cancer Research2021

Antitumor Activity of the Novel BTK Inhibitor TG-1701 Is Associated with Disruption of Ikaros Signaling in Patients with B-cell Non-Hodgkin Lymphoma.

Marcelo Lima Ribeiro et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.